Novozymes adjusted net profit excl. PPA rises 8% in H1 FY26; adjusted EBITDA margin climbs 30 bps to 37.7%
Reuters2026/08/19 15:42- Novozymes posted 8% organic sales growth in H1 2026, including a ~1.5 percentage-point drag from exiting certain countries.
- Adjusted EBITDA margin edged up 30 basis points year-on-year to 37.7%, despite a currency headwind.
- Adjusted net profit excluding PPA rose 8% from a year earlier.
- Free cash flow before acquisitions came in at 14% of sales; NIBD/EBITDA was 1.8x, with CAPEX at 9.7% of sales.
- Raised 2026 organic sales growth outlook to 7%-8%; expects adjusted EBITDA margin at the higher end of 37%-38%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Faraday Future adds government procurement veteran Steven Newton as senior strategic advisor
JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet
JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."
FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans
Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric
Crypto prices
More
